性别在局部晚期微卫星高度不稳定胃癌或胃食管结合部癌中的预后与预测作用:随机临床试验个体患者数据汇总分析
该研究对MAGIC、CLASSIC、ITACA-S和ARTIST四项随机试验的个体患者数据进行汇总分析,评估性别在局部晚期胃癌/胃食管结合部癌中的预后和预测作用。结果显示,在MSS/MSI-low肿瘤中,女性5年OS为63.2%对男性57.6%(HR 0.842;p=0.058),5年DFS为55.8%对50.8%(HR 0.850;p=0.0504);MSI-high肿瘤中化疗的不良效应在女性中数值上更大。
要点
- 在MSS/MSI-low胃癌/胃食管结合部癌中,女性5年OS数值上长于男性(63.2%对57.6%,HR 0.842;p=0.058)。
- 在MSS/MSI-low肿瘤中,女性5年DFS数值上长于男性(55.8%对50.8%,HR 0.850;p=0.0504)。
- MSI-high肿瘤中化疗不良效应的数值差异在女性中大于男性。
核心结论
- 该汇总分析纳入四项随机试验,强调性别在MSI-high和MSS/MSI-low非转移性胃癌/胃食管结合部癌的预后和治疗疗效中具有相关影响。
研究设计与样本
- 对MAGIC、CLASSIC、ITACA-S和ARTIST四项随机临床试验的个体患者数据进行汇总分析,纳入接受单纯手术或手术联合围手术期/辅助化疗的胃癌/胃食管结合部癌患者。
- 本分析为二次分析,评估性别(女性对男性)在总体人群及按MSI状态分层(MSI-high对MSS/MSI-low)患者中的预后和预测作用。
- 计算无病生存期(DFS)和总生存期(OS)。
主要发现
- 无论性别,MSI-high肿瘤患者较MSS/MSI-low患者生存改善。
- 在MSS/MSI-low肿瘤患者中,女性5年OS为63.2%对男性57.6%(HR 0.842;p=0.058),女性5年DFS为55.8%对男性50.8%(HR 0.850;p=0.0504)。
- MSI-high胃癌中化疗不良效应的数值差异在女性中大于男性。
- 在MSS/MSI-low胃癌中,无论性别,化疗较单纯手术的显著获益得到确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery plus peri-operative/adjuvant chemotherapy is the standard of care for locally advanced GC/GEJC, though with unsatisfactory results. dMMR/MSI-high tumors have better prognosis and scant benefit from chemotherapy as compared to pMMR/MSS ones. The differential outcome of therapies in terms of safety and efficacy according to sex is still debated in GC/GEJC patients. METHODS: We previously performed an individual patient data pooled analysis of MAGIC, CLASSIC, ITACA-S, and ARTIST trials including GC/GEJC patients treated with surgery alone or surgery plus peri-operative/adjuvant chemotherapy to assess the value of MSI status. We performed a secondary analysis investigating the prognostic and predictive role of sex (female versus male) in the pooled analysis dataset in the overall population and patients stratified for MSI status (MSI-high versus MSS/MSI-low). Disease-free (DFS) and overall survival (OS) were calculated. RESULTS: Patients with MSI-high tumors had improved survival as compared to MSS/MSI-low ones irrespective of sex, whereas in those with MSS/MSI-low tumors, females had numerically longer OS and DFS (5-year OS was 63.2% versus 57.6%, HR 0.842; p = 0.058, and 5-year DFS was 55.8% versus 50.8%, HR 0.850; p = 0.0504 in female versus male patients). The numerical difference for the detrimental effect of chemotherapy in MSI-high GC was higher in females than males, while the significant benefit of chemotherapy over surgery alone was confirmed in MSS/MSI-low GC irrespective of sex. CONCLUSIONS: This pooled analysis including four randomized trials highlights a relevant impact of sex in the prognosis and treatment efficacy of MSI-high and MSS/MSI-low non-metastatic GC/GEJC.
引用
- Raimondi A, Kim YW, Kang WK, et al. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials. Eur J Cancer. 2024. PMID: 38598921. doi:10.1016/j.ejca.2024.114043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。